Cancers Attributable to Infectious Agents: an Ecological Study in Asia
DOI:
https://doi.org/10.31557/apjec.2018.1.1.35-40Keywords:
Cancer- Infectious agents- AsiaAbstract
Infections are a major contributor to cancer, especially in developing countries. Infections through the virus, bacteria and parasites are the most and most preventable causes of cancer in the world. The aim of the current study was to investigate the epidemiology of cancer-related infections in Asia. We considered 4 infectious agents classified as carcinogenic to human beings by the International Agency for Research on Cancer. We calculated the number of new cancer cases in 2012 attributable to infections by country, by combining cancer incidence estimates (from GLOBOCAN 2012) with the estimates of attributable fraction (AF) for the infectious agents. AF estimates were calculated from the prevalence of infection in cancer cases for the infection (for some sites). According to data registered in 2012, about 14 million new cases of cancer were detected worldwide of which 2. 2 million people (15.4%) diagnosed with cancer due to infection. The highest incidence of infectious cancers related to the African continent with a prevalence of 27.6% followed by Asian continents (21.4%), America (7.9%), Europe (7.3%) and Oceania (4.8%), respectively. In the Asian continent, of all cancers associated with infection in males, 48.1% were related to Helicobacter pylori infection, 33.2% of hepatitis B virus, 8% of hepatitis C and 3.3% of HPV and in women 47.4% HPV, 28.7% Helicobacter pylori, 15.3% Hepatitis B and 4.5% Hepatitis C, respectively. India (230,000 cases) and Japan (140,000 cases) were the most affected, while Bahrain (86 cases) and Brunei (88 cases) had the least cases of infection-related cancer. in Asia, the most common cancer-related infection in males and females were reported for Helicobacter pylori and HPV, respectively. Therefore, with preventive interventions aimed at reducing these infections, the burden of cancers can be reduced.
References
Casper C, Fitzmaurice C. Infection-related cancers: prioritising an important and eliminable contributor to the global cancer burden. The Lancet Global Health. 2016;4(9):e580-e1.
De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The lancet oncology. 2012;13(6):607-15.
Moradi G, Goodarzi E, Khazaei Z. Prevalence of Hepatitis B and C in prisons worldwide: A meta-analysis during the years 2005-2015. Biomedical Research and Therapy. 2018;5(4):2235-51.
Antonsson A, Wilson LF, Kendall BJ, Bain CJ, Whiteman DC, Neale RE. Cancers in Australia in 2010 attributable to infectious agents. Australian and New Zealand journal of public health. 2015;39(5):446-51.
Lu T, Seto W-K, Zhu R-X, Lai C-L, Yuen M-F. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World Journal of Gastroenterology: WJG. 2013;19(47):8887.
Maucort‐Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. International journal of cancer. 2018;142(12):2471-7.
Afsar Kazerooni P, Khazaei Z, Mousavi M, Khazaei S, Sohrabivafa M, Dehghani SL, et al. Prevalence of human immunodeficiency virus and tuberculosis among homeless individuals. Immunopathol Persa. 2018.
Mousavi Movahhed SM BMS, Hayati F, Shayanpour S, Halili SA, Leila Sabetnia L, Khazaei Z. . The relationship between chronic kidney disease and cancer. J Nephropathol. 2018;7(3):115-16.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64(1):9-29.
Talebi Bezmin Abadi A. Therapy of Helicobacter pylori: present medley and future prospective. BioMed Research International. 2014;2014.
Lee Y-C, Chiang T-H, Chou C-K, Tu Y-K, Liao W-C, Wu M-S, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150(5):1113-24. e5.
Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papillomavirus infection. Sexual health. 2010;7(3):244-52.
Chaichian S, Khateri S, Moradi Y, Shadmani FK, Mansori K, Khazaei Z, et al. Trends in Cervical Cancer Incidence in Iran from 2003 to 2009. Middle East Journal of Cancer. 2017;9(1):57-63.
Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. Journal of Infectious Diseases. 2010;202(12):1789-99.
Herrero R, González P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. The Lancet Oncology. 2015;16(5):e206-e16.
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiology and Prevention Biomarkers. 2016;25(1):16-27.
Norouzirad R, Khazaei Z, Mousavi M, Adineh HA, Hoghooghi M, Khabazkhoob M, et al. Epidemiology of common cancers in Dezful county, southwest of Iran. Immunopathologia Persa. 2017;4(1).
Mirzaei M, Sharifnia G, Khazaei Z, Sadeghi E, Fallahzadeh H, Namayandeh SM. Prevalence of general obesity and central adiposity and its related factors in adult population of Yazd. SSU_Journals. 2017;25(9):736-47.
Vineis P, Wild CP. Global cancer patterns: causes and prevention. The Lancet. 2014;383(9916):549-57.
Davoodi M BS, Bahadoram M, Barahman M, Khazaei Z, Amiri M. . Impact of cancers on the kidney function and structure; an ignored entity. . J Renal Inj Prev. 2018;7(3):112-5.
Oh J-K, Weiderpass E. Infection and cancer: global distribution and burden of diseases. Annals of global health. 2014;80(5):384-92.
Hunt R, Xiao S, Megraud F, Leon-Barua R, Bazzoli F, Van der Merwe S, et al. Helicobacter pylori in developing countries. World gastroenterology organisation global guideline. J Gastrointestin Liver Dis. 2011;20(3):299-304.
Bornschein J, Rokkas T, Selgrad M, Malfertheiner P. Gastric cancer: clinical aspects, epidemiology and molecular background. Helicobacter. 2011;16(s1):45-52.
Malfertheiner P, Fry LC, Mönkemüller K. Can gastric cancer be prevented by Helicobacter pylori eradication? Best Practice & Research Clinical Gastroenterology. 2006;20(4):709-19.
De Vries A, Kuipers E. Helicobacter pylori eradication for the prevention of gastric cancer. Alimentary pharmacology & therapeutics. 2007;26(s2):25-35.
Maddah G, Abdollahi A, Khajeh Karamadini M, Nakhaeizadeh S, Jabbari Noughabi A, Jangjoo A, et al. Evaluation incidence of Helicobacter pylori infection in gastric adenocarsinoma. The Horizon of Medical Sciences. 2014;19(4):212-7.
Fakour F, Bodaghi N, Hajizadeh Fallah H, Etezadi A. Survey of Serum Level of High Risk Human Papilloma Virus Antibodies in Patients with Cervical Cancer and CIN I, II, III in Pap Smears. Journal of Guilan University of Medical Sciences. 2016;25(97):12-9.
Castellsagué X, Naud P, Chow S-N, Wheeler CM, Germar MJV, Lehtinen M, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. The Journal of infectious diseases. 2014;210(4):517-34.
3.jpg)
